EP Patent

EP4653047A2 — Mifepristone for use in improving insulin sensitivity

Assigned to Individual · Expires 2025-11-26 · 0y expired

What this patent protects

The invention relates to the amelioration of a disorder of insulin sensitivity, which entails administering an amount of one or more glucocorticoid receptor antagonists effective to ameliorate the disorder with no more than an acceptable activation of the hypothalamic-pituitary-a…

USPTO Abstract

The invention relates to the amelioration of a disorder of insulin sensitivity, which entails administering an amount of one or more glucocorticoid receptor antagonists effective to ameliorate the disorder with no more than an acceptable activation of the hypothalamic-pituitary-adrenal axis, such that 24 hour serum or urine cortisol levels do not exceed about two to three times the upper normal limit, respectively.

Drugs covered by this patent

Patent Metadata

Patent number
EP4653047A2
Jurisdiction
EP
Classification
—
Expires
2025-11-26
Drug substance claim
No
Drug product claim
No
Assignee
Individual
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.